AbbVie announces positive phase 3 results for Parkinson’s drug
These results back up results from the TEMPO-3 trial, which tested tavapadon as an add-on therapy to levodopa and which also met its primary endpoint earlier this year. The final trial, TEMPO-2 is testing flexible dose tavapadon, also as a monotherapy, and is expected to read out before the end of the year.